At this time, I would like to welcome everyone to the Antigenics second quarter 2010 earnings call. (Operator Instructions) I will now turn the call over to Ms. Sharp, Vice President and CFO. Shalini Sharp Welcome to Antigenics conference call to discuss the financial results for the quarter ended June 30, 2010. With me today is Dr. Garo Armen, Chairman and CEO. We hope that all of you have had a chance to review the press release that was issued this morning. During this call, we will review the financial results as well as provide a corporate update. We will then have a Q&A session. But before we continue, I would like to remind you that this conference call will contain forward-looking statements, including without limitation statements regarding the company's cash position, timing of potential royalty streams and development and commercialization efforts, timelines, availability of data and potential efficacy with respect to products and product candidates of the company and/or its licensees and partners. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. Reference to these risks and uncertainties is made in today's press release and they're disclosed in more detail in our most recent filings with the U.S. SEC. These statements speak only as of the date of this call and Antigenics undertakes no obligation to update or revise these statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. When evaluating Antigenics' business and securities, investors should give careful consideration to these risks and uncertainties.